Legend Biotech Corporation - American Depositary Shares (LEGN)

Baidu is transitioning from a search-driven advertising company into an AI infrastructure and enterprise cloud provider in China. HHLR’s exit comes as investors weigh whether this transformation will lead to sustainable growth.

Even after cutting back, this remains the fund’s largest bet and the timing lines up with a pivotal stretch for Arcutis’ pipeline.

When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next.

Inside the Fintech Platform Winning Over a New Generation of Investors in Asia

XP’s New Backer Sees Opportunity in Brazil’s Next Financial Chapter

Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.

Thousand Oaks, CA – October 2, 2025 – Amgen (NASDAQ: AMGN) has witnessed a robust surge in its share price, climbing approximately 6% in recent trading sessions, culminating on October 2, 2025, to reach $296.93 USD. This significant uptick is attributed to a powerful combination of strategic manufacturing investments, a pivotal

Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings. These reports, ranging from cybersecurity and fintech to mining and life sciences, offer a crucial granular view into

Legend Biotech's Q2 2025 earnings show revenue beat at $255.1M, driven by strong CARVYKTI sales, but EPS missed at -$0.34. Stock rose 1.4% pre-market.

Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.